LXEO at a glance
Lexeo Therapeutics, Inc. (LXEO, SEC CIK 1907108) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Lexeo Therapeutics, Inc. (LXEO) shares worth $111.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Townsend Richard Nolan on November 17, 2026 of 3,295 shares at $3.26 per share.
- In the last 90 days, LXEO insiders reported 0 open-market purchases ($0) and 3 open-market sales ($18K) on Form 4, a net sale of $18K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$18K
- 13F holders
- 28 funds
- $111.6M · +2 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 8.01 · Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales generated
- Net loss $38.3M vs $20.3M YoY, operating loss $40.4M vs $21.6M
- LX2006 R&D $12.7M vs $5.1M, best-performing program by quarterly spending
- Cash, equivalents and Treasury investments $219.1M vs $246.6M at year-end; operating cash outflow $67.3M
- Management expects funding into 2028, with continued losses and significantly higher development expenses ahead
Risk Factors
- Newly added regulatory risk: 2026 legislation codified orphan exclusivity by approved indication and extended pediatric priority vouchers only through September 30, 2029
- Most materially updated FDA risk: agency reorganization, potential shutdowns, layoffs, and resource constraints could delay reviews, approvals, and inspections
- Clinical safety risk: LX2006 preclinical studies observed four hepatocellular carcinomas in wild-type mice 10 months after treatment
- Competitive risk: LX2006 faces Solid Biosciences, Voyager-Neurocrine, Larimar, Design Therapeutics, and PTC Therapeutics programs
- Liquidity risk: $219.1 million in cash, cash equivalents, and U.S. Treasury investments expected to fund operations into 2028
AI summary of the LXEO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Positive interim Phase I/II data announced for LX2020 targeting PKP2-associated arrhythmogenic cardiomyopathy
- Regulatory updates for LX2020 create potential development-pathway implications
Item 2.02: Results of Operations and Financial Condition
- Press release covers Lexeo’s business highlights and financial results for the three and nine months ended September 30, 2026
- Investors should review Exhibit 99.1 for earnings figures, cash position, pipeline updates and forward operating implications
Item 7.01: Regulation FD Disclosure
- Corporate presentation attached as Exhibit 99.2 for the referenced webcast
- Investor relevance depends on pipeline, clinical, regulatory, or financing updates in the presentation
Item EX-99.3: Item EX-99.3
- Corporate overview highlights LX2006 as Lexeo’s lead FA-cardiomyopathy asset, with potential first disease-modifying gene therapy in a high-unmet-need market
- SUNRISE-FA 2 pivotal study initiated June 2026, enrolling 26 participants with 13 treated at 1.2×10¹² vg/kg
Item EX-99.1: Item EX-99.1
- High-dose LX2020 cohorts showed 80% mean NSVT reduction and 44% mean PVC reduction at latest assessment, supporting clinical proof-of-concept
- FDA openness to NSVT as a primary surrogate endpoint strengthens potential accelerated-approval pathway, with pivotal design expected in 1H 2027
Item EX-99.2: Item EX-99.2
- Phase 1/2 HEROIC-PKP2 interim data: high-dose LX2020 reduced mean NSVT 80% and PVC burden 44% at latest assessment, n=7
- Five of seven high-dose participants reported symptom improvement, while cardiac MRI showed stabilization or improvement in most participants
Item 3.02: Unregistered Sales of Equity Securities
- Common Stock issued in the Merger, creating potential dilution for existing Lexeo shareholders
- Shares issued without Securities Act registration under Section 4(a)(2) and/or Regulation D exemptions
Item 2.01: Completion of Acquisition or Disposition of Assets
- Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo shares, subject to closing adjustments
- Up to $1.0M additional cash contingent on specified events, creating potential future acquisition cost
Item 8.01: Other Events
- Merger Agreement with Mantle Therapeutics and strategic collaborations mark a potentially transformative corporate development
- Expected merger closing and contingent consideration remain subject to conditions and execution risks
Item 1.01: Entry into a Material Definitive Agreement
- Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo stock, subject to adjustments
- Up to $13.0M additional contingent consideration, including $1.0M cash and $12.0M milestone payments over 12 years
Item EX-99.1: Item EX-99.1
- Mantle acquisition adds four FA programs across oral, protein-replacement, and ASO modalities for $8.3M upfront
- Potential consideration reaches $21.3M, including $13.0M in success-based milestones
Item EX-99.2: Item EX-99.2
- Mantle acquisition adds four FA programs spanning oral, protein-replacement and RNA approaches, broadening Lexeo beyond LX2006’s cardiac focus
- Upfront consideration $8.3M, with success-based milestones up to $13M, payable in cash and equity
AI summaries of LXEO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LXEO
Don't miss the next LXEO filing
- Alerts as it files. A push when LXEO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LXEO, by share count.
- Ask anything. An AI agent that reads every LXEO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Townsend Richard Nolan | Sell | Nov 17, 2026 | 3,295 | $3.26 |
| Tamayo Louis Edward | Sell | Nov 17, 2026 | 1,007 | $3.26 |
| Otero Jose Manuel | Sell | Nov 17, 2026 | 1,285 | $3.26 |
| Schilke Tobin | A | Nov 14, 2026 | 70,000 | - |
| Bhalla Narinder Pal | A | Sep 24, 2026 | 54,750 | - |
| Townsend Richard Nolan | A | Sep 24, 2026 | 145,500 | - |
| Otero Jose Manuel | A | Sep 24, 2026 | 54,750 | - |
| Tamayo Louis Edward | A | Sep 24, 2026 | 54,750 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$68.5M | -$105.8M | -$109.3M |
| Net Income | -$66.4M | -$98.3M | -$100.0M |
| Balance Sheet | |||
| Total Assets | $139.8M | $146.9M | $268.7M |
| Equity | - | $116.8M | $246.7M |
| ROE | - | -84.2% | -40.5% |
| Per Share | |||
| EPS | $-12.40 | $-3.09 | $-1.86 |
| Cash Flow | |||
| Operating CF | -$59.5M | -$81.2M | -$98.6M |
| CapEx | $115K | $481K | $397K |
Source: XBRL data in Lexeo Therapeutics, Inc. (LXEO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LXEO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $111.6M |
| Q2 2026 | 26 | $130.5M |
| Q1 2026 | 25 | $138.0M |
| Q4 2025 | 26 | $223.1M |
| Q3 2025 | 23 | $95.8M |
| Q2 2025 | 20 | $51.5M |
| Q1 2025 | 17 | $24.7M |
| Q4 2024 | 11 | $38.8M |
- JPMorgan Chase & Co+4.49M (+4660%)
- Millennium Management+944.9K (+33%)
- Citadel Advisors LLC+338.4K (+9%)
- BlackRock+234.2K (+4%)
- Renaissance Technologies LLC+121.2K (+48%)
- State Street Corp−760.7K (-17%)
- Morgan Stanley−237.9K (-60%)
- Goldman Sachs Group−172.0K (-8%)
- Vanguard Portfolio Management LLC−130.9K (-21%)
- Dimensional Fund Advisors−95.4K (-7%)
- Ameriprise Financial+260.8K
- Two Sigma Investments+92.0K
- M&T Bank+10.9K
- FMR LLC (Fidelity)−141.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 176 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LXEO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 10-Q | Nov 16, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
LXEO SEC filings: frequently asked questions
Are LXEO insiders buying or selling?
In the last 90 days, Lexeo Therapeutics, Inc. (LXEO) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $18,214 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LXEO stock?
As of September 30, 2026, the largest Lexeo Therapeutics, Inc. (LXEO) holders among the 13F filers tracked by SignalX were BlackRock ($20.2 million), JPMorgan Chase & Co ($15.7 million), Citadel Advisors LLC ($14.3 million), Millennium Management ($12.8 million), State Street Corp ($12.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did LXEO report in its latest 8-K?
Lexeo Therapeutics, Inc. (LXEO) filed an 8-K on November 16, 2026 reporting Item 8.01 (Other Events), Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Positive interim Phase I/II data announced for LX2020 targeting PKP2-associated arrhythmogenic cardiomyopathy.
What are the latest LXEO SEC filings?
Lexeo Therapeutics, Inc. (LXEO) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 18, 2026.
What is LXEO's SEC CIK number?
Lexeo Therapeutics, Inc. (LXEO)'s SEC Central Index Key (CIK) is 1907108. EDGAR lists every LXEO filing under that number.
Ask anything about LXEO
The research agent reads LXEO's filings, financials, insider trades and 13F holders, then answers with sources.